Patents by Inventor Rina J. MEPANI

Rina J. MEPANI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240141386
    Abstract: Nucleic acids and viral vectors, particularly adeno-associated virus (AAV) vectors are provided that encode Cas9 and paired guide RNAs. The nucleic acids and vectors, and compositions that comprise them, can be used in methods to treat subjects, to alter cells in subjects who may suffer from an inherited retinal dystrophy such as CEP290 associated disease or who may be in need of alteration of a cell or a cellular nucleic acid sequence associated with an inherited retinal dystrophy such as the CEP290 gene, and/or to treat inherited retinal dystrophies including CEP290 associated disease.
    Type: Application
    Filed: January 30, 2023
    Publication date: May 2, 2024
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, Michael STEFANIDAKIS
  • Publication number: 20230295725
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 21, 2023
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
  • Publication number: 20230038993
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Application
    Filed: February 2, 2021
    Publication date: February 9, 2023
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
  • Patent number: 11566263
    Abstract: Nucleic acids and viral vectors, particularly adeno-associated virus (AAV) vectors are provided that encode Cas9 and paired guide RNAs. The nucleic acids and vectors, and compositions that comprise them, can be used in methods to treat subjects, to alter cells in subjects who may suffer from an inherited retinal dystrophy such as CEP290 associated disease or who may be in need of alteration of a cell or a cellular nucleic acid sequence associated with an inherited retinal dystrophy such as the CEP290 gene, and/or to treat inherited retinal dystrophies including CEP290 associated disease.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: January 31, 2023
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee Maeder, Rina J. Mepani, Michael Stefanidakis
  • Publication number: 20220273818
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Application
    Filed: October 11, 2021
    Publication date: September 1, 2022
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
  • Patent number: 11339437
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: May 24, 2022
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee Maeder, Rina J. Mepani, David A. Bumcrot, Shen Shen, Michael Stefanidakis
  • Patent number: 11141493
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: October 12, 2021
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee Maeder, Rina J. Mepani, David A. Bumcrot, Shen Shen, Michael Stefanidakis
  • Publication number: 20190201550
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Application
    Filed: August 2, 2018
    Publication date: July 4, 2019
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
  • Publication number: 20190169652
    Abstract: Nucleic acids and viral vectors, particularly adeno-associated virus (AAV) vectors are provided that encode Cas9 and paired guide RNAs. The nucleic acids and vectors, and compositions that comprise them, can be used in methods to treat subjects, to alter cells in subjects who may suffer from an inherited retinal dystrophy such as CEP290 associated disease or who may be in need of alteration of a cell or a cellular nucleic acid sequence associated with an inherited retinal dystrophy such as the CEP290 gene, and/or to treat inherited retinal dystrophies including CEP290 associated disease.
    Type: Application
    Filed: August 2, 2017
    Publication date: June 6, 2019
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, Michael STEFANIDAKIS
  • Publication number: 20180155789
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Application
    Filed: August 2, 2017
    Publication date: June 7, 2018
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS